Ex-Merck R&D chief Kim to teach at Stanford med school

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Merck's Kim resigns to teach at Stanford med school

Peter Kim, the former R&D chief at Merck ($MRK), is joining Stanford University School of Medicine as a professor of biochemistry. Among his most notable research projects at Merck, Kim oversaw the development of a leading human papilloma virus (HPV) vaccine, as well as vaccines for rotavirus and shingles. Kim, though, exited Merck earlier this year after the company had endured a 7-year drought of new blockbusters. "We saw some wonderful successes, together with some pretty visible failures," he said. "That comes with the game." Med school dean Lloyd Minor noted that "with his many years as an innovative researcher and his extensive work in developing and shepherding drugs to market, Peter exemplifies our commitment to ensuring patients we see in our clinics benefit from the discoveries we make in our laboratories." More

Peter Kim stepped down as president of Merck Research Laboratories.

Teva Pharmaceutical Industries
Moshe Many stepped down as VP of the board of directors.


Teva's ($TEVA) vice chairman of its board of directors, Moshe Many, will step down from his post at the beginning of 2014 to be replaced by board member Amir Elstein. Many will remain a member of the board. Release

Ton Berkien joined Nuevolution as the company's chief business officer. Berkien most recently was in charge of corporate development at Takeda. Release

Kamada appointed Amir London as its senior vice president of business development. Release

ThromboGenics brought on Staf Van Reet as the chairman of its board of directors. Release

Michael Metzger joined Regado Biosciences ($RGDO) as the company's president and chief operating officer. Release

The Female Health Company named Karen King as its president and CEO. King has worked with Baxter International ($BAX) and Royal DSM. Release

USDM Life Sciences appointed Wilfredo Santiago as its senior manager of manufacturing systems. Santiago has consulted for Johnson & Johnson ($JNJ), Eli Lilly ($LLY), Sartorius, Pfizer ($PFE) and Genentech. Release

Robert Pierce joined OncoSec Medical as chief medical officer. Previously, Pierce was executive director at Merck Research Labs. Release

Advanced Cell Technology appointed Dr. Eddy Anglade to the newly created position of executive vice president of clinical development. Anglade joins ACT after co-founding Lux Pharmaceuticals and serving as its chief medical officer. Release

David Moore, chief business officer of Ocera Therapeutics ($OCRX), is leaving the company to pursue other opportunities. Rhonda Stanley, Ocera's controller and principal accounting officer, will also be leaving Ocera. Release

Momenta Pharmaceuticals ($MNTA) named Dr. Michael Franken president, biosimilars business. Prior to joining Momenta, Franken served as senior vice president and chief business officer of Radius Health. Release

Dr. Georges Gemayel joined Prosensa ($RNA) as a supervisory board member. Most notably, Gemayel served as executive vice president at Genzyme from 2003 to 2008. Release

Boston Therapeuticas appointed Edward Shea as vice president, business development; Tina Gagnon as consulting director of finance; and Yael Bobruff clinical affairs manager. Release


Itonis Pharmaceuticals appointed Ernesto Barron to be the company's chief scientific officer and director of clinical research. Release

InVivo Therapeutics bumped William D'Agostino and Robert Ham up to vice president of manufacturing and engineering and senior director of quality, respectively. Release

Bristol-Myers Squibb ($BMY) named Thomas Lynch, Jr., to the company's board of directors. Release

Relmada Therapeutics appointed Douglas Beck as its chief financial officer. Release


Quintiles ($Q) appointed W. Scott Evangelista to serve as president, integrated commercial services and solutions. Evangelista joins Quintiles from Deloitte Consulting. Release

Harlan appointed Hiroharu Okochi as president of Harlan Japan. Previously, Okochi was responsible for sales and business development of Covance ($CVD) central laboratory services to Japanese pharmaceutical companies. Release